Skip to content

2 papers indexed here

We haven’t gathered this author’s papers yet. Follow them and we’ll fetch their work.

Not the right person? Other researchers publish under this name.

Open access Oct 2026

PRO-C6 and endotrophin are associated with cardiac remodelling and adverse outcomes in HFpEF: data from the prospective NETDiamond cohort

Heart failure with preserved ejection fraction (HFpEF) is characterized by extracellular matrix (ECM) remodelling and fibrosis, but clinically useful circulating biomarkers reflecting these processes remain limited. To assess whether circulating ECM-derived biomarkers (PRO-C3, PRO-C6 and endotrophin) are a...

F. Vasques-Nóvoa, E. Angeli, M. Karsdal et al. · 0 citations
Open access Oct 2026

The antifibrotic effect of empagliflozin: Insights from the EMPIRE trial programme

Treatment with empagliflozin significantly decreased levels of circulating PRO-C3, reflecting attenuated systemic fibroblast activation, and to what extent this indicated antifibrotic effect may underpin the clinical effects of empagliflozin remains to be elucidated.

J. Jensen, C. Andersen, M. Omar et al. · 0 citations

We use cookies to run the site and, with your consent, for analytics and to show ads. See our Cookie Policy.